Wei Songfeng, Gao Ming, Zhao Cui, Pan Yi, Li Haixin, Li Jian, Li Xiaolong
Department of Head and Neck Tumor, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Huanhuxi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Int J Clin Oncol. 2014 Oct;19(5):800-4. doi: 10.1007/s10147-013-0620-z. Epub 2013 Oct 5.
A decreased radioiodine uptake is associated with high recurrence rate and reduced survival in papillary thyroid carcinoma (PTC). Sodium iodide symporter (NIS) expression status in aggressive PTC variants is unknown.
NIS expression in conventional PTC and aggressive PTC variants such as tall cell variant (TCV) and diffuse sclerosing variant (DSPTC) was investigated using immunohistochemical detection.
Patients having TCV and DSPTC were significantly more likely to have extrathyroidal extension and lymph nodes metastases (P < 0.05). Positive NIS staining was identified in 228 of 312 (73.1 %) patients with conventional PTC, 9 of 28 (32.1 %) patients with TCV and 12 of 30 (40.0 %) patients with DSPTC. NIS expression distinguished conventional PTC from TCV and DSPTC significantly (P < 0.01).
Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis.
放射性碘摄取减少与甲状腺乳头状癌（PTC）的高复发率及生存率降低相关。侵袭性PTC变异型中碘化钠转运体（NIS）的表达状况尚不清楚。
采用免疫组化检测法研究常规PTC以及侵袭性PTC变异型如高细胞变异型（TCV）和弥漫硬化变异型（DSPTC）中NIS的表达。
患有TCV和DSPTC的患者更易出现甲状腺外侵犯和淋巴结转移（P<0.05）。在312例常规PTC患者中有228例（73.1%）NIS染色呈阳性，28例TCV患者中有9例（32.1%）呈阳性，30例DSPTC患者中有12例（40.0%）呈阳性。NIS表达将常规PTC与TCV和DSPTC显著区分开来（P<0.01）。
由于TCV和DSPTC的NIS表达较低，需要更高的放射性碘治疗累积剂量以改善其预后。
